David Baxley Spetzler Sells 119,212 Shares of Caris Life Sciences (NASDAQ:CAI) Stock

Caris Life Sciences, Inc. (NASDAQ:CAI) President David Baxley Spetzler sold 119,212 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $24.76, for a total value of $2,951,689.12. Following the transaction, the president owned 1,182,871 shares of the company’s stock, valued at $29,287,885.96. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Baxley Spetzler also recently made the following trade(s):

• On Thursday, September 3rd, David Baxley Spetzler sold 478,000 shares of Caris Life Sciences stock. The stock was sold at an average price of $24.86, for a total transaction of $11,883,080.00.

Caris Life Sciences Price Performance

Caris Life Sciences stock opened at $25.07 on Friday. The company has a market cap of $7.08 billion, a price-to-earnings ratio of 69.64 and a beta of 1.10. The firm’s fifty day moving average is $19.98 and its 200 day moving average is $18.85. The company has a quick ratio of 4.88, a current ratio of 5.53 and a debt-to-equity ratio of 0.66. Caris Life Sciences, Inc. has a 52-week low of $14.19 and a 52-week high of $36.65.

Caris Life Sciences declared that its Board of Directors has approved a share repurchase program on Monday, June 8th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to repurchase up to 2.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CAI. Wolfe Research cut shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. BTIG Research boosted their price objective on Caris Life Sciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Evercore reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Caris Life Sciences in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Caris Life Sciences from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.33.

Institutional Investors Weigh In On Caris Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in CAI. ProShare Advisors LLC purchased a new position in shares of Caris Life Sciences during the 4th quarter worth about $336,000. Global Retirement Partners LLC raised its position in Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares during the period. Seven Grand Managers LLC lifted its stake in Caris Life Sciences by 395.1% in the fourth quarter. Seven Grand Managers LLC now owns 495,095 shares of the company’s stock worth $13,358,000 after purchasing an additional 395,095 shares during the last quarter. Norges Bank purchased a new position in shares of Caris Life Sciences during the fourth quarter valued at approximately $2,976,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Caris Life Sciences by 57,052.2% during the fourth quarter. BNP Paribas Financial Markets now owns 685,826 shares of the company’s stock valued at $18,504,000 after buying an additional 684,626 shares during the period.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.